1. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
by Kerry J. Savage, Brian Skinnider, Mubarak Al-Mansour, Laurie H. Sehn, Randy D. Gascoyne, and Joseph M. Connors
Blood
Volume 118(17):
October 27, 2011
©2011 by American Society of Hematology

2. Outcome of limited stage NLPHL
Outcome of limited stage NLPHL. (A) Era-to-era comparison of TTP of limited-stage NLPHL treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .0074).
Outcome of limited stage NLPHL. (A) Era-to-era comparison of TTP of limited-stage NLPHL treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .0074). (B) Era-to-era comparison of PFS of limited-stage NLPHL treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .0024). (C) Era-to-era comparison of OS limited-stage NLPHL patients treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .074).
Kerry J. Savage et al. Blood 2011;118:
©2011 by American Society of Hematology

3. Progression or treatment failure rates from reports evaluating the treatment of limited-stage NLPHL.
Kerry J. Savage et al. Blood 2011;118:
©2011 by American Society of Hematology